Weekly Investment Analysts’ Ratings Changes for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ: GILD) recently received a number of ratings updates from brokerages and research firms:

• 2/18/2025 – Gilead Sciences was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating. They now have a $120.00 price target on the stock, up previously from $80.00.
• 2/13/2025 – Gilead Sciences was upgraded by analysts at DZ Bank AG from a “hold” rating to a “buy” rating. They now have a $108.00 price target on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $84.00 to $90.00. They now have a “sector perform” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $105.00 to $120.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Piper Sandler from $105.00 to $110.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $113.00 to $123.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $110.00 to $115.00. They now have an “outperform” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $85.00 to $96.00. They now have a “neutral” rating on the stock.
• 2/12/2025 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 2/3/2025 – Gilead Sciences had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $84.00 price target on the stock.
• 1/29/2025 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $105.00 to $115.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Gilead Sciences was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $113.00 price target on the stock, up previously from $87.00.

Gilead Sciences Trading Up 1.0 %

GILD stock opened at $111.03 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $111.99. The stock has a market capitalization of $138.37 billion, a price-to-earnings ratio of 300.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The firm’s fifty day simple moving average is $95.79 and its two-hundred day simple moving average is $89.08.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.85%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 706,212 shares of company stock valued at $67,324,826 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Bellevue Group AG increased its position in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares during the period. Quantinno Capital Management LP increased its position in Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares during the period. McAdam LLC increased its position in Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares during the period. IRON Financial LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $830,000. Finally, Capital Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.